A clinically compatible drug‐screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis
L Zhu, D Retana, P García‐Gómez… - EMBO molecular …, 2022 - embopress.org
We report a medium‐throughput drug‐screening platform (METPlatform) based on
organotypic cultures that allows to evaluate inhibitors against metastases growing in situ. By
applying this approach to the unmet clinical need of brain metastasis, we identified several
vulnerabilities. Among them, a blood–brain barrier permeable HSP90 inhibitor showed high
potency against mouse and human brain metastases at clinically relevant stages of the
disease, including a novel model of local relapse after neurosurgery. Furthermore, in situ …
organotypic cultures that allows to evaluate inhibitors against metastases growing in situ. By
applying this approach to the unmet clinical need of brain metastasis, we identified several
vulnerabilities. Among them, a blood–brain barrier permeable HSP90 inhibitor showed high
potency against mouse and human brain metastases at clinically relevant stages of the
disease, including a novel model of local relapse after neurosurgery. Furthermore, in situ …
[PDF][PDF] A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis
A Hernández-Laın, O Toldos, Y Ruano, L Alcázar… - 2022 - e-archivo.uc3m.es
We report a medium-throughput drug-screening platform (METPlatform) based on
organotypic cultures that allows to evaluate inhibitors against metastases growing in situ. By
applying this approach to the unmet clinical need of brain metastasis, we identified several
vulnerabilities. Among them, a blood–brain barrier permeable HSP90 inhibitor showed high
potency against mouse and human brain metastases at clinically relevant stages of the
disease, including a novel model of local relapse after neurosurgery. Furthermore, in situ …
organotypic cultures that allows to evaluate inhibitors against metastases growing in situ. By
applying this approach to the unmet clinical need of brain metastasis, we identified several
vulnerabilities. Among them, a blood–brain barrier permeable HSP90 inhibitor showed high
potency against mouse and human brain metastases at clinically relevant stages of the
disease, including a novel model of local relapse after neurosurgery. Furthermore, in situ …
以上显示的是最相近的搜索结果。 查看全部搜索结果